Semaglutide
Price on application
Semaglutide is a long-acting GLP-1 receptor agonist with 94% homology to native human GLP-1. It features a C-18 fatty diacid chain enabling albumin binding, resulting in a half-life of approximately 7 days and once-weekly dosing.
Research Profile
Semaglutide is a modified GLP-1(7-37) analog with two key modifications: an Aib substitution at position 2 to resist DPP-4 cleavage, and a C-18 fatty diacid side chain at Lys26 that promotes non-covalent albumin binding. These changes extend its half-life to approximately 165 hours, enabling once-weekly subcutaneous administration. Semaglutide activates GLP-1 receptors in the pancreas to enhance glucose-dependent insulin secretion and suppress glucagon. In the brain, it acts on hypothalamic appetite centers to reduce food intake and body weight. FDA-approved as Ozempic (diabetes) and Wegovy (obesity), semaglutide has demonstrated up to 15-17% body weight reduction in clinical trials. An oral formulation (Rybelsus) using the SNAC absorption enhancer is also available.
Technical Details
- Chemical Formula
- C187H291N45O59
- Synonyms
- Semaglutide, Ozempic, Wegovy, Rybelsus, NN9535
- Molecular Weight
- 4113.58 g/mol
- CAS Number
- 910463-68-2
- Appearance
- Lyophilized White Powder
- Purity
- >98% (HPLC Verified)
- Shelf Life
- 36 months (Store at 2-8°C)